Biosight is a private Phase 2 clinical stage biotech company, developing innovative therapeutics for hematological malignancies and disorders.
Biosight’s lead product, BST-236 (INN aspacytarabine), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity.
BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of ac...
Biosight is a private Phase 2 clinical stage biotech company, developing innovative therapeutics for hematological malignancies and disorders.
Biosight’s lead product, BST-236 (INN aspacytarabine), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity.
BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging Phase 1/2a, which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard therapy.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.